KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Second Fiscal Quarter Results : vimarsana.com

- Preparing for Initiation of KVD900 Phase 3 Clinical Trial- - KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling - - Funded Beyond Data on Both HAE Trials - KalVista Pharmaceuticals, Inc. (NASDAQ:

Related Keywords

Leah Monteiro , Andrew Crockett , Exchange Commission , Kalvista Pharmaceuticals Inc , American College Of Allergy , Corporate Communications Investor Relations , Nasdaq , Trial Enrolling , Beyond Data , Vista Pharmaceuticals , Chief Executive Officer , Fiscal Quarter , Recent Business Highlights , American College , Asthma Immunology , Annual Scientific , Fiscal Quarter Financial Results , Kalvista Pharmaceuticals , Securities Litigation Reform Act , Consolidated Statement , Consolidated Statements , Kalvista , Harmaceuticals , Eports , Econd , Iscal , Uarter , Esults ,